PEPTIDESTAT
ApprovedClinical / approved drugIntranasalEvidence 5/5

Desmopressin

Also known as: DDAVP, Stimate, Nocdurna

Desmopressin selectively stimulates renal V2 vasopressin receptors to increase water reabsorption (antidiuresis) while also triggering release of factor VIII and von Willebrand factor from vascular endothelium.

Read guideBuy / compare source
Desmopressin
Drug class
Synthetic vasopressin (V2 receptor) analog; antidiuretic and hemostatic peptide
Primary targets
Vasopressin V2 receptor
Dose reference
Reference ranges from labels (not recommendations): central diabetes insipidus intranasal 10-40 mcg/day or oral 0.1-1.2 mg/day divided; primary nocturnal enuresis oral 0.2-0.6 mg at bedtime; nocturia (sublingual) 27.7 mcg women / 55.3 mcg men at bedtime; bleeding disorders IV 0.3 mcg/kg over 15-30 minutes.
Half-life
Roughly 1.5-3.5 hours depending on route (terminal half-life about 2.8 hours after IV dosing; ~3.3-3.5 hours intranasal)
Developer / origin
Ferring Pharmaceuticals (peptide first synthesized by Zaoral and colleagues in the 1960s)
Reference year
1978
Evidence score
5/5 - Strong, well-established clinical evidence

Approved uses

  • Central (cranial) diabetes insipidus
  • Primary nocturnal enuresis
  • Nocturia due to nocturnal polyuria
  • Mild-to-moderate hemophilia A (hemostasis)
  • Type 1 von Willebrand disease (hemostasis)
Evidence 5/5

Strong, well-established clinical evidence

Desmopressin is an FDA-approved peptide with decades of label-backed and trial evidence across antidiuretic and hemostatic indications, supported by primary sources from FDA/DailyMed labels and peer-reviewed journals.

Approved medication with substantial human clinical evidence.

Evidence basis

  • FDA and DailyMed prescribing information for DDAVP, Nocdurna and desmopressin nasal/tablet formulations establish V2-mediated antidiuresis and approved indications
  • Landmark Mannucci 1977 Lancet study and 20- and 30-year reviews document hemostatic factor VIII/vWF release in hemophilia A and type 1 von Willebrand disease
  • Randomized controlled trials and contemporary reviews support low-dose, sex-specific desmopressin for nocturia with serum sodium monitoring to manage hyponatremia

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.

Desmopressin guides

Read the matching guide or adjacent research pages for more context.

Desmopressin Peptide: DDAVP, Stimate, Nocdurna Uses and SafetyDesmopressin is an approved synthetic vasopressin V2 analog with antidiuretic and hemostatic uses, strong label evidence, and a central hyponatremia safety limit.Abaloparatide Peptide: Tymlos, PTHrP Analog Uses and Safety LimitsAbaloparatide is an FDA-approved PTHrP(1-34) analog peptide that builds bone in high-risk osteoporosis, backed by the ACTIVE and ATOM trials with clear duration and safety limits.Atosiban Peptide: Tractocile, Oxytocin Antagonist Tocolytic for Preterm LaborAtosiban is an EU-approved oxytocin and vasopressin receptor antagonist peptide used intravenously as a short-term tocolytic to delay preterm labor.Bivalirudin Peptide: Angiomax Direct Thrombin Inhibitor GuideBivalirudin is an FDA-approved, hirudin-derived bivalent direct thrombin inhibitor used as a short-acting intravenous anticoagulant during percutaneous coronary intervention.

Peptide calculators

Use calculators for concentration, unit conversion and repeated-dose accumulation math.

Peptide reconstitution calculatorCalculate concentration, draw volume and syringe units from vial strength and BAC water.Open toolPeptide accumulation calculatorModel repeated dosing schedules with half-life, interval, peak and trough estimates.Open toolPeptide unit converterConvert mg, mcg, optional IU and syringe units from one reconstituted vial setup.Open toolPeptide chemistry calculatorAnalyze sequence length, molecular weight, composition, charge, hydropathy and notation.Open tool

Compare with related peptides

Stay inside the same research category and compare mechanism, status and evidence quality.

Larazotide

Larazotide acetate, AT-1001

2/5
Clinical / approved drugInvestigational

An oral, gut-restricted peptide that antagonizes zonulin signaling to limit gluten-driven intestinal tight-junction permeability in celiac disease.

DetailsGuide

Lanreotide

Somatuline Depot, Somatuline Autogel

5/5
Clinical / approved drugApproved

Lanreotide binds with high affinity to somatostatin receptors 2 and 5, mimicking native somatostatin to suppress growth hormone, IGF-1 and various neuroendocrine and gut hormones.

DetailsGuide

Teriparatide

Forteo, Bonsity, PTH 1-34

4/5
Clinical / approved drugApproved

Once-daily injection produces intermittent activation of the PTH1 receptor on osteoblasts, preferentially stimulating bone formation over resorption to increase bone mass.

DetailsGuide
4/5
Clinical / approved drugApproved

Abaloparatide is a PTHrP(1-34) analog that agonizes the PTH1 receptor with preference for its transient RG conformation, activating cAMP signaling to stimulate osteoblast-driven new bone formation.

DetailsGuide

Research & educational purposes only

The information on PeptideStat is for educational and research purposes only and is not medical advice. Many peptides discussed are research compounds not approved for human use. Always consult a qualified healthcare professional before making any health decisions. Articles may contain affiliate links — we may earn a commission at no extra cost to you.